Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | NCOA2 | Q15596 | 2/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | STAT1 | P42224 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29479590 | 1.00 | MAPT (0.51) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL23012765 | 1.00 | MAPT (0.51) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30850818 | 0.89 | ALDH1A1 (0.49) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL23012294 | 0.89 | ALDH1A1 (0.49) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29479820 | 0.86 | MAPT (0.50) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL23033392 | 0.86 | MAPT (0.50) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29479722 | 0.86 | NPC1 (0.54) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL28707250 | 0.86 | NPC1 (0.54) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL28713327 | 0.85 | KDM4E (0.61) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30297422 | 0.85 | KDM4E (0.61) | MAPTKDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092768-A1 | CRYSTAL FORM OF ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD FOR CRYSTAL FORM, AND USE OF CRYSTAL FORM | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-03-21 | — | — | US | disclosed |
| US-20240043416-A1 | SALT AND CRYSTAL FORM OF HA INHIBITOR COMPOUND | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-02-08 | — | — | US | disclosed |
| EP-4289826-A1 | SALT AND CRYSTAL FORM OF HA INHIBITOR COMPOUND | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-12-13 | — | — | EP | disclosed |
| EP-4282860-A1 | CRYSTAL FORM OF ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD FOR CRYSTAL FORM, AND USE OF CRYSTAL FORM | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| CN-114269725-A | Anti-influenza virus compound and preparation method and application thereof | 四川海思科制药有限公司 | 2022-04-01 | — | — | CN | disclosed |
| WO-2021032209-A1 | ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD AND USE THEREOF | 四川海思科制药有限公司 | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092768-A1 | CRYSTAL FORM OF ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD FOR CRYSTAL FORM, AND USE OF CRYSTAL FORM | ZC3HAV1, ZC3HAV1L, FMNL1 | MAPT 1387/4885KDM4E 182/4885ALDH1A1 1568/4885 |
| US-20240043416-A1 | SALT AND CRYSTAL FORM OF HA INHIBITOR COMPOUND | MMP11, MMP1, MMP2 | MAPT 2436/4885KDM4E 2318/4885ALDH1A1 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.